Management of Triglycerides at 363 mg/dL
For an adult with triglycerides of 363 mg/dL, initiate or maximize statin therapy as the foundation of treatment, address all secondary causes (particularly diabetes, obesity, and alcohol use), implement dietary modifications with reduced added sugars and refined carbohydrates, and consider adding icosapent ethyl (EPA) if the patient has established ASCVD or diabetes with additional cardiovascular risk factors despite statin therapy. 1, 2
Risk Stratification and Primary Concern
At 363 mg/dL, this patient has moderate hypertriglyceridemia (200-499 mg/dL range). The primary concern here is atherosclerotic cardiovascular disease (ASCVD) risk reduction, not acute pancreatitis, which becomes the dominant concern only when triglycerides exceed 500-1,000 mg/dL 1, 3.
Step 1: Identify and Address Secondary Causes
Before initiating pharmacotherapy, systematically evaluate for:
- Diabetes mellitus and glycemic control - Poor glucose control directly elevates triglycerides 1
- Obesity and metabolic syndrome - Weight loss independently reduces triglycerides 3, 4
- Alcohol consumption - Should be eliminated or significantly reduced 1, 2
- Medications that raise triglycerides (thiazides, beta-blockers, estrogens, corticosteroids, antiretrovirals)
- Hypothyroidism, chronic kidney disease, nephrotic syndrome 1
Step 2: Lifestyle Interventions (Foundation of Therapy)
Dietary modifications should be implemented immediately, ideally through medical nutrition therapy with a registered dietitian nutritionist 5, 6:
- Reduce added sugars and refined carbohydrates - These directly increase triglyceride synthesis
- Limit total fat intake to 20-40 g/day for moderate hypertriglyceridemia 2
- Replace simple carbohydrates with unsaturated fatty acids and protein 4
- Implement evidence-based cardioprotective dietary patterns (Mediterranean-style diet) 4
- Eliminate or minimize alcohol 1, 2
Physical activity is a cornerstone intervention that independently lowers triglycerides 4
Weight loss if overweight/obese - This has triglyceride-lowering effects independent of other interventions 4
Step 3: Statin Therapy (First-Line Pharmacotherapy)
Initiate or maximize statin therapy regardless of LDL-C level 1, 2:
- Statins are the first-line pharmacologic treatment because ASCVD risk is the primary clinical concern at this triglyceride level 3
- Use moderate-to-high intensity statin based on overall cardiovascular risk profile 2
- This is particularly important if the patient has diabetes mellitus or established ASCVD 1
Step 4: Consider Triglyceride Risk-Based Nonstatin Therapy
Add icosapent ethyl (EPA) 4 g/day if the patient meets specific criteria 1, 7, 6:
- Triglycerides ≥150 mg/dL despite maximally tolerated statin therapy, AND
- Either established ASCVD OR diabetes mellitus with ≥2 additional cardiovascular risk factors
The evidence supporting this approach:
- The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events with EPA-only (icosapent ethyl) in high-risk patients with hypertriglyceridemia on statin therapy 7
- EPA-only does not raise LDL-C, unlike EPA+DHA formulations 7
- At 4 g/day, prescription omega-3 fatty acids reduce triglycerides by ≥30% 7
Alternative considerations:
- Prescription omega-3 fatty acids (EPA+DHA) can be used if EPA-only is not available, though they may modestly increase LDL-C 7
- Fibrates are reserved primarily for preventing acute pancreatitis when triglycerides approach or exceed 500 mg/dL 1
Step 5: Monitoring and Reassessment
- Recheck lipid panel in 4-12 weeks after initiating therapy
- Monitor adherence to lifestyle modifications and pharmacotherapy 1
- Reassess secondary causes if triglycerides remain persistently elevated
- If triglycerides increase toward 500 mg/dL, intensify dietary fat restriction and consider fibrate therapy to prevent pancreatitis 1
Important Caveats
Common pitfalls to avoid:
- Do not delay statin therapy while waiting for lifestyle modifications alone - statins should be initiated concurrently 1, 3
- Do not use over-the-counter fish oil supplements expecting cardiovascular benefit - only prescription omega-3 fatty acids at 4 g/day have demonstrated cardiovascular risk reduction 7
- At this triglyceride level (363 mg/dL), non-HDL cholesterol is a better marker of atherogenic risk than LDL-C alone 8, 6
- Referral to registered dietitian nutritionists is historically underutilized but critical for optimal management 5
The nuance in the evidence: Recent data suggest that the cardiovascular risk gradient may be less steep in the 200-500 mg/dL range compared to the full biological range of triglycerides 9. However, this does not negate the importance of treatment, particularly in high-risk patients where icosapent ethyl has proven cardiovascular benefit 7.